Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection
Authors:
- Nuray UsluNUNuray Uslu
- Gokhan BaysoyGBGokhan Baysoy
- Hulya DemirHDHulya Demir
- Inci Nur Saltik TemizelITInci Nur Saltik Temizel
- Aysel YuceAYAysel Yuce
- 31 May 2010
- journal article
- case report
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48 (1) , 66-68
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis CHaematologica, 2008
- Safety and efficacy of pegylated interferon -2a and ribavirin for the treatment of hepatitis C in patients with thalassemiaHaematologica, 2008
- Treatment of hepatitis C in patients with thalassemiaHaematologica, 2008
- Efficacy and Safety of Peginterferon-α2b and Ribavirin Combination Therapy in Children With Chronic Hepatitis C InfectionThe Pediatric Infectious Disease Journal, 2008
- Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis CPharmacoepidemiology and Drug Safety, 2007
- Response to Pegylated Interferon α-2b and Ribavirin in Children With Chronic Hepatitis CJournal of Clinical Gastroenterology, 2007
- Treatment of Hepatitis C Virus Infection in ThalassemiaAnnals of the New York Academy of Sciences, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995